# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

ιBN		
1 009	221 783	
Part	ne entity) give ASX the followin  1 - All issues  1 st complete the relevant sections (att	g information.  Fach sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	125,000,000
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares
4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:	Yes

Name of entity

**ENTELLECT LIMITED** 

<sup>+</sup> See chapter 19 for defined terms.

	<ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
5	Issue price or consideration	1.	25,000,000 shares were issued upon the exercise of options at an exercise price of \$0.001 per share (total consideration \$25,000).
		2.	100,000,000 shares were issued upon the conversion of 4 convertible notes which were issued on 6 December 2013. The subscription price per convertible note was \$25,000 (total subscription price \$100,000).
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	1.	25,000,000 shares issued upon the exercise of 25,000,000 options. The options were issued as free attaching options to holders of convertible notes to incentivise note holders.
		2.	100,000,000 shares issued upon conversion of 4 convertible notes issued on 6 December 2013. The convertible notes were issued to raise general working capital for the Company.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes	
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i		
6b	The date the security holder resolution under rule 7.1A was passed	29	November 2013
6c	Number of *securities issued without security holder approval under rule 7.1	Nil	
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	

- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 25,000,000 ordinary shares are issued upon the exercise of 25,000,000 options. The issue of the options, which are free attaching options to convertible notes, was approved by shareholders on 29 November 2013.
- 2. 100,000,000 ordinary shares are issued upon conversion of 4 convertible notes, in accordance with shareholder approval obtained on 29 November 2013.
- 6f Number of \*securities issued under an exception in rule 7.2

Nil

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.

N/A

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

See Annexure 1

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

- 10 January 2014
- 8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
2,151,122,932	Fully paid ordinary shares

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
38	Convertible Notes
425,000,000	Options
89,000,000	Performance Rights

<sup>+</sup> See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	
	increased capital (interests)	

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
22	Foo or commission possible to	N/A
23	Fee or commission payable to the broker to the issue	N/A

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Part 3 - Quotation of securities

You ne	ed only	complete this section if you are	applying for quotation of securities	
34	Type of +securities (tick one)			
(a)		+Securities described in Part	:1	
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entit	ies th	nat have ticked box 3	4(a)	
Addit	ional	securities forming a new	class of securities	
Tick to docume		e you are providing the informati	on or	
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36		If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37		A copy of any trust deed for	the additional *securities	
Entities that have ticked box 34(b)				
38		per of *securities for which ation is sought	N/A	
39		s of *securities for which tion is sought	N/A	

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
Reason for request for quotation now	N/A	
Example: In the case of restricted securities, end of restriction period		
(if issued upon conversion of another *security, clearly identify that other *security)		
	Niversia	Ι.
Number and talege of all		+Class N/A
*securities quoted on ASX (including the *securities in clause 38)	IV/A	IV/A
	all respects from the +issue date with an existing +class of quoted +securities?  If the additional +securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)  Number and +class of all +securities quoted on ASX (including the +securities in	all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)  Number  Number and *class of all *securities quoted on ASX (including the *securities in

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*guotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

SOPHIE KARZIS Company Secretary 10 January 2014

# **Appendix 3B – Annexure 1**

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	1,130,122,932 fully paid ordinary shares	
Add the following:		
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	Nil	
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	<ul> <li>100,518,420 shares issued on 11 March 2013</li> <li>70,481,580 shares issued on 11 March 2013</li> <li>100,000,000 shares issued on 30 April 2013</li> <li>10,168,440 shares issued on 7 June 2013</li> <li>200,000,000 shares issued on 29 July 2013</li> <li>30,000,000 shares issued on 5 August 2013</li> <li>25,000,000 shares issued on 6 December 2013</li> <li>100,000,000 shares issued on 10 December 2013</li> <li>75,000,000 shares issued on 18 December 2013</li> <li>25,000,000 shares issued on 23 December 2013</li> <li>125,000,000 shares issued on 10 January 2014</li> </ul>	
Number of partly paid *ordinary securities that became fully paid in that 12 month period  Note:	N/A	
<ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	Nil	
"A"	1,991,291,372	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	298,693,706

# Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

**Insert** number of \*equity securities issued or agreed to be issued in that 12 month period *not counting* those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 or rule 7.4

#### Note:

- This applies to equity securities, unless specifically excluded – not just ordinary securities
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

3 convertible notes, each with a face value of \$25,000 (and an aggregate value of \$75,000) (**Notes**), which if collectively converted at the conversion price of \$0.001, will be converted into **75,000,000** underlying conversion shares\*.

75,000,000 free attaching options to the Notes, which if collectively exercised, will be converted into **75,000,000** underlying shares\*.

\*these 150,000,000 underlying shares have NOT been issued by the Company.

"C" 150,000,000

# Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15  Note: number must be same as shown in Step 2	298,693,706
Subtract "C"  Note: number must be same as shown in Step 3	150,000,000
<i>Total</i> ["A" x 0.15] – "C"	148,693,706 [Note: this is the remaining placement capacity under rule 7.1]

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Step 2: Calculate 10% of "A"	
"D"	0.10  Note: this value cannot be changed
Multiply "A" by 0.10	199,129,137
Step 3: Calculate "E", the amount of phas already been used	lacement capacity under rule 7.1A that
<ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	<ul> <li>14,831,560 ordinary shares issued on 7 June 2013</li> <li>35,000,000 ordinary shares issued on 5 August 2013</li> <li>80,000,000 ordinary shares issued on 24 October 2013</li> <li>30,000,000 ordinary shares issued on 30 October 2013</li> </ul>
"E"	159,831,560
Step 4: Subtract "E" from ["A" x "D"] capacity under rule 7.1A	to calculate remaining placement
"A" x 0.10	199,129,137
Note: number must be same as shown in Step 2	
Subtract "E"	159,831,560
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" × 0.10] – "E"	39,297,577
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.